Morphea (localized scleroderma)

Noelle M. Teske, Heidi T. Jacobe

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Morphea, also called localized scleroderma, is a sclerosing skin disorder that resembles scleroderma (systemic sclerosis) in terms of cutaneous histopathological features, but differs demographically and clinically. Hallmark clinical and serological features of scleroderma (sclerodactyly, Raynaud’s phenomenon, internal organ involvement, and scleroderma-specific antibodies) are absent in morphea. Affecting adults and children equally, morphea is characterized by single or multiple indurated cutaneous plaques that can have variable appearance depending on the subtype and activity of disease. The predominant subtypes are circumscribed or plaque-type, linear, generalized, pansclerotic, and mixed morphea. Treatment of morphea, which may include corticosteroids, methotrexate, and/or phototherapy, is aimed at shutting down inflammation in active morphea and preventing cosmetic/functional impairment that may result from unabated activity.

Original languageEnglish (US)
Title of host publicationScleroderma
Subtitle of host publicationFrom Pathogenesis to Comprehensive Management
PublisherSpringer International Publishing
Pages91-113
Number of pages23
ISBN (Electronic)9783319314075
ISBN (Print)9783319314051
DOIs
StatePublished - Jan 1 2016

Fingerprint

Localized Scleroderma
Skin
Raynaud Disease
Phototherapy
Systemic Scleroderma
Methotrexate
Cosmetics
Adrenal Cortex Hormones
Inflammation
Antibodies

Keywords

  • Classification of morphea
  • Clinical features of morphea
  • Localized forms of scleroderma
  • Morbidity in morphea
  • Morphea
  • Treatment in morphea

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Teske, N. M., & Jacobe, H. T. (2016). Morphea (localized scleroderma). In Scleroderma: From Pathogenesis to Comprehensive Management (pp. 91-113). Springer International Publishing. https://doi.org/10.1007/978-3-319-31407-5_8

Morphea (localized scleroderma). / Teske, Noelle M.; Jacobe, Heidi T.

Scleroderma: From Pathogenesis to Comprehensive Management. Springer International Publishing, 2016. p. 91-113.

Research output: Chapter in Book/Report/Conference proceedingChapter

Teske, NM & Jacobe, HT 2016, Morphea (localized scleroderma). in Scleroderma: From Pathogenesis to Comprehensive Management. Springer International Publishing, pp. 91-113. https://doi.org/10.1007/978-3-319-31407-5_8
Teske NM, Jacobe HT. Morphea (localized scleroderma). In Scleroderma: From Pathogenesis to Comprehensive Management. Springer International Publishing. 2016. p. 91-113 https://doi.org/10.1007/978-3-319-31407-5_8
Teske, Noelle M. ; Jacobe, Heidi T. / Morphea (localized scleroderma). Scleroderma: From Pathogenesis to Comprehensive Management. Springer International Publishing, 2016. pp. 91-113
@inbook{def4c356790b43ea9209a744bad34ba3,
title = "Morphea (localized scleroderma)",
abstract = "Morphea, also called localized scleroderma, is a sclerosing skin disorder that resembles scleroderma (systemic sclerosis) in terms of cutaneous histopathological features, but differs demographically and clinically. Hallmark clinical and serological features of scleroderma (sclerodactyly, Raynaud’s phenomenon, internal organ involvement, and scleroderma-specific antibodies) are absent in morphea. Affecting adults and children equally, morphea is characterized by single or multiple indurated cutaneous plaques that can have variable appearance depending on the subtype and activity of disease. The predominant subtypes are circumscribed or plaque-type, linear, generalized, pansclerotic, and mixed morphea. Treatment of morphea, which may include corticosteroids, methotrexate, and/or phototherapy, is aimed at shutting down inflammation in active morphea and preventing cosmetic/functional impairment that may result from unabated activity.",
keywords = "Classification of morphea, Clinical features of morphea, Localized forms of scleroderma, Morbidity in morphea, Morphea, Treatment in morphea",
author = "Teske, {Noelle M.} and Jacobe, {Heidi T.}",
year = "2016",
month = "1",
day = "1",
doi = "10.1007/978-3-319-31407-5_8",
language = "English (US)",
isbn = "9783319314051",
pages = "91--113",
booktitle = "Scleroderma",
publisher = "Springer International Publishing",

}

TY - CHAP

T1 - Morphea (localized scleroderma)

AU - Teske, Noelle M.

AU - Jacobe, Heidi T.

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Morphea, also called localized scleroderma, is a sclerosing skin disorder that resembles scleroderma (systemic sclerosis) in terms of cutaneous histopathological features, but differs demographically and clinically. Hallmark clinical and serological features of scleroderma (sclerodactyly, Raynaud’s phenomenon, internal organ involvement, and scleroderma-specific antibodies) are absent in morphea. Affecting adults and children equally, morphea is characterized by single or multiple indurated cutaneous plaques that can have variable appearance depending on the subtype and activity of disease. The predominant subtypes are circumscribed or plaque-type, linear, generalized, pansclerotic, and mixed morphea. Treatment of morphea, which may include corticosteroids, methotrexate, and/or phototherapy, is aimed at shutting down inflammation in active morphea and preventing cosmetic/functional impairment that may result from unabated activity.

AB - Morphea, also called localized scleroderma, is a sclerosing skin disorder that resembles scleroderma (systemic sclerosis) in terms of cutaneous histopathological features, but differs demographically and clinically. Hallmark clinical and serological features of scleroderma (sclerodactyly, Raynaud’s phenomenon, internal organ involvement, and scleroderma-specific antibodies) are absent in morphea. Affecting adults and children equally, morphea is characterized by single or multiple indurated cutaneous plaques that can have variable appearance depending on the subtype and activity of disease. The predominant subtypes are circumscribed or plaque-type, linear, generalized, pansclerotic, and mixed morphea. Treatment of morphea, which may include corticosteroids, methotrexate, and/or phototherapy, is aimed at shutting down inflammation in active morphea and preventing cosmetic/functional impairment that may result from unabated activity.

KW - Classification of morphea

KW - Clinical features of morphea

KW - Localized forms of scleroderma

KW - Morbidity in morphea

KW - Morphea

KW - Treatment in morphea

UR - http://www.scopus.com/inward/record.url?scp=85018873555&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85018873555&partnerID=8YFLogxK

U2 - 10.1007/978-3-319-31407-5_8

DO - 10.1007/978-3-319-31407-5_8

M3 - Chapter

AN - SCOPUS:85018873555

SN - 9783319314051

SP - 91

EP - 113

BT - Scleroderma

PB - Springer International Publishing

ER -